Novel aspects of atypical haemolytic uraemic syndrome and the role of eculizumab

Nephrology Dialysis Transplantation

Volumn 29, Issue , 2014, Pages iv131-iv141

  Verhave, Jacobien C ^a   Wetzels, Jack F M ^a   Van De Kar, Nicole C A J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Atypical haemolytic uraemic syndrome; Complement; Eculizumab; Renal transplantation

Indexed keywords

ANTIBIOTIC AGENT; COMPLEMENT COMPONENT C3; COMPLEMENT FACTOR H; COMPLEMENT FACTOR I; ECULIZUMAB; MEMBRANE COFACTOR PROTEIN; MENINGOCOCCUS VACCINE; THROMBOMODULIN; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; COMPLEMENT; MONOCLONAL ANTIBODY;

BRAIN INFARCTION; C3 GENE; CFH GENE; CFHR1 GENE; CFHR2 GENE; CFHR3 GENE; CFHR4 GENE; CFHR5 GENE; CFI GENE; COHORT ANALYSIS; COMPLEMENT BLOOD LEVEL; DIARRHEA; DISEASE ASSOCIATION; DISEASE COURSE; DNA POLYMORPHISM; DRUG EFFICACY; DRUG SAFETY; END STAGE RENAL DISEASE; EPIDEMIC MENINGITIS; GAIN OF FUNCTION MUTATION; GENE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; HEADACHE; HEMATOLOGIC DISEASE; HEMOLYSIS; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPERTENSION; HYPOCOMPLEMENTEMIA; INNATE IMMUNITY; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LOSS OF FUNCTION MUTATION; MCP GENE; PATHOGENESIS; PLASMA EXCHANGE; PLASMA TRANSFUSION; PLASMAPHERESIS; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; STENOSIS; THBD GENE; THROMBOCYTOPENIA; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VISUAL DISORDER; VOMITING; ATYPICAL HAEMOLYTIC URAEMIC SYNDROME;

ATYPICAL HAEMOLYTIC URAEMIC SYNDROME; COMPLEMENT; ECULIZUMAB; RENAL TRANSPLANTATION;

ANTIBODIES, MONOCLONAL, HUMANIZED; HEMOLYTIC-UREMIC SYNDROME; HUMANS; TREATMENT OUTCOME;

EID: 84910147270     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfu235     Document Type: Review

References (75)

1. Remuzzi G. HUS and TTP: variable expression of a single entity. Kidney Int 1987; 32: 292-308
2. Furlan M, Robles R, Galbusera M et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolyticuremic syndrome. N Engl J Med 1998; 339: 1578-1584
3. Gasser C, Gautier E, Steck A et al. Hemolytic-uremic syndrome: bilateral necrosis of the renal cortex in acute acquired hemolytic anemia. Schweiz MedWochenschr 1955; 85: 905-909
4. Drukker A, Winterborn M, Bennett B et al. Recurrent hemolytic-uremic syndrome: a case report. Clin Nephrol 1975; 4: 68-72
5. Spirer Z, Knobel B, Earon J et al. Recurrent hemolytic-uremic syndrome. A report of two cases. Helv Paediatr Acta 1977; 32: 165-172
6. Barre P, Kaplan BS, de Chadarevian JP et al. Hemolytic uremic syndrome with hypocomplementemia, serum C3NeF, and glomerular deposits of C3. Arch Pathol Lab Med 1977; 101: 357-361
7. Thompson RA, Winterborn MH. Hypocomplementaemia due to a genetic deficiency of beta 1H globulin. Clin Exp Immunol 1981; 46: 110-119
8. Gruppo RA, Rother RP. Eculizumab for congenital atypical hemolyticuremic syndrome. N Engl J Med 2009; 360: 544-546
9. Nurnberger J, Philipp T, Witzke O et al. Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med 2009; 360: 542-544
10. Dragon-Durey MA, Loirat C, Cloarec S et al. Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol 2005; 16: 555-563
11. Westra D, Wetzels JF, Volokhina EB et al. A new era in the diagnosis and treatment of atypical haemolytic uraemic syndrome. Neth J Med 2012; 70: 121-129
12. Rosales A, Hofer J, Zimmerhackl LB et al. Need for long-term follow-up in enterohemorrhagic Escherichia coli-associated hemolytic uremic syndrome due to late-emerging sequelae. Clin Infect Dis 2012; 54: 1413-1421
13. Noris M, Mescia F, Remuzzi G. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol 2012; 8: 622-633
14. Geerdink LM, Westra D, van Wijk JA et al. Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics. Pediatr Nephrol 2012; 27: 1283-1291
15. Fremeaux-Bacchi V, Fakhouri F, Garnier A et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol 2013; 8: 554-562
16. Trachtman H, Austin C, Lewinski M et al. Renal and neurological involvement in typical Shiga toxin-associated HUS. Nat Rev Nephrol 2012; 8: 658-669
17. Steinborn M, Leiz S, Rudisser K et al. CT and MRI in haemolytic uraemic syndrome with central nervous system involvement: distribution of lesions and prognostic value of imaging findings. Pediatr Radiol 2004; 34: 805-810
18. Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA et al. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2007; 18: 2392-2400
19. Holers VM. Complement and its receptors: new insights into human disease. Annu Rev Immunol 2014; 32: 433-459
20. Delvaeye M, Noris M, De Vriese A et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361: 345-357
21. Warwicker P, Goodship TH, Donne RL et al. Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int 1998; 53: 836-844
22. Richards A, Kemp EJ, Liszewski MK et al. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci U S A 2003; 100: 12966-12971
23. Fremeaux-Bacchi V, Dragon-Durey MA, Blouin J et al. Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome. J Med Genet 2004; 41: e84
24. Goicoechea de Jorge E, Harris CL, Esparza-Gordillo J et al. Gain-offunction mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci U S A 2007; 104: 240-245
25. Fremeaux-Bacchi V, Miller EC, Liszewski MK et al. Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood 2008; 112: 4948-4952
26. Sinibaldi S, Guzzo I, Piras R et al. Post-transplant recurrence of atypical hemolytic uremic syndrome in a patient with thrombomodulin mutation. Pediatr Transplant 2013; 17: E177-E181
27. Lemaire M, Fremeaux-Bacchi V, Schaefer F et al. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet 2013; 45: 531-536
28. Noris M, Caprioli J, Bresin E et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010; 5: 1844-1859
29. Loirat C, Fremeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis 2011; 6: 60
30. Caprioli J, Noris M, Brioschi S et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 2006; 108: 1267-1279
31. Bresin E, Rurali E, Caprioli J et al. Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. J Am Soc Nephrol 2013; 24: 475-486
32. Waters A. Optimizing treatment strategies in paediatric atypical hemolytic uremic syndrome. Pediatr Nephrol 2011; 26: 1917-1918
33. Westra D, Volokhina E, van der Heijden E et al. Genetic disorders in complement (regulating) genes in patients with atypical haemolytic uraemic syndrome (aHUS). Nephrol Dial Transplant 2010; 25: 2195-2202
34. Skerka C, Chen Q, Fremeaux-Bacchi V et al. Complement factor H related proteins (CFHRs). Mol Immunol 2013; 56: 170-180
35. Heinen S, Sanchez-Corral P, Jackson MS et al. De novo gene conversion in the RCA gene cluster (1q32) causes mutations in complement factor H associated with atypical hemolytic uremic syndrome. Hum Mutat 2006; 27: 292-293
36. Jozsi M, Licht C, Strobel S et al. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood 2008; 111: 1512-1514
37. Dragon-Durey MA, Blanc C, Marliot F et al. The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome. J Med Genet 2009; 46: 447-450
38. Hofer J, Janecke AR, Zimmerhackl LB et al. Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2013; 8: 407-415
39. Moore I, Strain L, Pappworth I et al. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood 2010; 115: 379-387
40. Esparza-Gordillo J, Goicoechea de Jorge E, Buil A et al. Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32. Hum Mol Genet 2005; 14: 703-712
41. Harris CL, Heurich M, Rodriguez de Cordoba S et al. The complotype: dictating risk for inflammation and infection. Trends Immunol 2012; 33: 513-521
42. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361: 1676-1687
43. Jodele S, Licht C, Goebel J et al. Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Blood 2013; 122: 2003-2007
44. Fakhouri F, Roumenina L, Provot F et al. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol 2010; 21: 859-867
45. Noris M, Remuzzi G. Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantation. Curr Opin Nephrol Hypertens 2013; 22: 704-712
46. Boels MG, Lee DH, van den Berg BM et al. The endothelial glycocalyx as a potential modifier of the hemolytic uremic syndrome. Eur J Intern Med 2013; 24: 503-509
47. Kaplan BS, Meyers KE, Schulman SL. The pathogenesis and treatment of hemolytic uremic syndrome. J Am Soc Nephrol 1998; 9: 1126-1133
48. Loirat C, Garnier A, Sellier-Leclerc AL et al. Plasmatherapy in atypical hemolytic uremic syndrome. Semin Thromb Hemost 2010; 36: 673-681
49. Waters AM, Licht C. aHUS caused by complement dysregulation: new therapies on the horizon. Pediatr Nephrol 2011; 26: 41-57
50. Remuzzi G, Misiani R, Marchesi D et al. Treatment of the hemolytic uremic syndrome with plasma. Clin Nephrol 1979; 12: 279-284
51. Hollenbeck M, Zawischa U, Passlick-Deetjen J et al. Haemolytic-uraemic syndrome in adults. Lancet 1990; 336: 380
52. Noris M, Remuzzi G. Genetics and genetic testing in hemolytic uremic syndrome/thrombotic thrombocytopenic purpura. Semin Nephrol 2010; 30: 395-408
53. Sinha A, Gulati A, Saini S et al. Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children. Kidney Int 2014; 85: 1151-1160
54. Ariceta G, Besbas N, Johnson S et al. Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol 2009; 24: 687-696
55. Noris M, Remuzzi G. Cardiovascular complications in atypical haemolytic uraemic syndrome. Nat Rev Nephrol 2014; 10: 174-180
56. Le Quintrec M, Zuber J, Moulin B et al. Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant 2013; 13: 663-675
57. Artz MA, Steenbergen EJ, Hoitsma AJ et al. Renal transplantation in patients with hemolytic uremic syndrome: high rate of recurrence and increased incidence of acute rejections. Transplantation 2003; 76: 821-826
58. Hillmen P, Young NS, Schubert J et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006; 355: 1233-1243
59. Mache CJ, Acham-Roschitz B, Fremeaux-Bacchi V et al. Complement inhibitor eculizumab in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2009; 4: 1312-1316
60. Chatelet V, Fremeaux-Bacchi V, Lobbedez T et al. Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome. Am J Transplant 2009; 9: 2644-2645
61. Davin JC, Gracchi V, Bouts A et al. Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation. Am J Kidney Dis 2010; 55: 708-711
62. Legendre CM, Licht C, Loirat C. Eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013; 369: 1379-1380
63. Rathbone J, Kaltenthaler E, Richards A et al. A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS). BMJ Open 2013; 3: e003573
64. Legendre CM, Licht C, Muus P et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013; 368: 2169-2181
65. Zuber J, Le Quintrec M, Krid S et al. Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant 2012; 12: 3337-3354
66. Zuber J, Fakhouri F, Roumenina LT et al. French Study Group for a HCG. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 2012; 8: 643-657
67. Martin NG, Snape MD. A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: what do we know, and what are we yet to learn? Expert Rev Vaccines 2013; 12: 837-858
68. Struijk GH, Bouts AH, Rijkers GT et al. Meningococcal sepsis complicating eculizumab treatment despite prior vaccination. Am J Transplant 2013; 13: 819-820
69. Kielstein JT, Beutel G, Fleig S et al. Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry. Nephrol Dial Transplant 2012; 27: 3807-3815
70. Ardissino G, Testa S, Possenti I et al. Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases. Am J Kidney Dis 2014; doi: 10.1053/j.ajkd.2014.01.434. [Epub ahead of print]
71. Verhave JC, Westra D, van Hamersvelt HW et al. Living kidney transplantation in adult patients with atypical haemolytic uraemic syndrome. Neth J Med 2013; 71: 342-347
72. Oyen O, Strom EH, Midtvedt K et al. Calcineurin inhibitor-free immunosuppression in renal allograft recipients with thrombotic microangiopathy/hemolytic uremic syndrome. Am J Transplant 2006; 6: 412-418
73. Kirschfink M. Targeting complement in therapy. Immunol Rev 2001; 180: 177-189
74. Zhang Y, Nester CM, Holanda DG et al. Soluble CR1 therapy improves complement regulation in C3 glomerulopathy. J Am Soc Nephrol 2013; 24: 1820-1829
75. Holers VM, Rohrer B, Tomlinson S. CR2-mediated targeting of complement inhibitors: bench-to-bedside using a novel strategy for site-specific complement modulation. Adv Exp Med Biol 2013; 735: 137-154